Insulet Corporation PODD
Composite 53/100; the shares have moved about 54% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 24/100 — a strong mark against it.
Balance-sheet strength ranks 71/100 — a moderate point in its favour. Quality ranks 63/100 — a moderate point in its favour. Growth ranks 55/100 — a slight point in its favour.
Momentum ranks 24/100 — a strong mark against it. Valuation ranks 44/100 — a slight mark against it.
What the company does Insulet Corporation (PODD) designs, makes, and sells the Omnipod line of tubeless insulin pumps and automated insulin delivery systems for people with insulin-dependent diabetes. It also supplies proprietary insulin pods to Amgen for the Neulasta Onpro post-chemotherapy delivery kit.
Key financials PODD posts gross margin 71.1% and operating margin 16.2%, with ROE 26.0% and ROCE 17.3%. Revenue grew 30.7% year-over-year, but EPS fell -39.3%. Leverage is moderate (Debt/Equity 0.67) with interest coverage 6.61 and current ratio 2.48.
Stock health Momentum is weak: -1.80% over 3 months, -42.21% over 6 months, and -56.42% over 12 months. RSI(14) is 43.00, indicating neither overbought nor oversold conditions. The Sideravia score is 53.5, with Valuation 33.8 and Momentum 17.7.
Price vs fair value PODD trades at a discount of 19.90% versus the analyst mean target of 171.91. - Recent 2026 guidance reset and Q2 beat cited as sustainability questions (Zacks) - CEO insider purchase after 55% decline noted as mixed signal (Motley Fool) - Wall Street sentiment remains mixed (Barchart)
Looking forward Forward P/E of 23.58 and PEG of 1.68 reflect expectations for continued growth, but high multiples (P/E 26.89, EV/EBITDA 15.81) underscore sensitivity to execution and macro demand.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.